Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs
February 15, 2018 3:06 PM EST
BMO Capital raised its price target on Incyte (NASDAQ: INCY) to $175.00 (from $172.00) while maintaining an Outperform rating.
Analyst M. Ian Somaiya commented, "Despite strong fundamentals and a rich pipeline, investor focus remains singularly on the upcoming epacadostat Phase 3 melanoma data (ECHO-301), with positive... More
February 15, 2018 2:35 PM EST
(Updated - February 15, 2018 2:50 PM EST)
(updated to expand analyst comment)
SunTrust Robinson Humphrey analyst Peter Lawson reiterated a Buy rating and $155 price target on Incyte (NASDAQ: INCY)
Lawson calls Q4 "Minor Jakafi Miss, but Focus on Epacadostat Readouts in 2018." The... More
February 15, 2018 7:05 AM EST
Incyte (NASDAQ: INCY) reported Q4 EPS of ($0.71), which may not compare to the analyst estimate of ($0.40). Revenue for the quarter came in at $444 million versus the consensus estimate of $414.16 million.
Issues Jakafi FY 2018 guidance $1.35-1.40 billion
For earnings history and earnings-related data on Incyte (INCY) click here.
...
More
